Pancreatic Cancer, An Issue of Hematology/Oncology Clinics of North America

Brian M. Wolpin

Description

This issue of Hematology/Oncology Clinics of North America is devoted to Pancreatic Cancer. Guest Editor Brian Wolpin, MD has assembled a group of expert authors to review the following topics: Biology and genetics of pancreatic adenocarcinoma; Mouse models of pancreatic adenocarcinoma; Epidemiology and inherited predisposition for sporadic pancreatic adenocarcinoma; Familial pancreatic adenocarcinoma; Imaging and endoscopic approaches to pancreatic cancer; Diagnosis and management of pancreatic cystic neoplasms; Surgical management of pancreatic cancer; Peri-operative therapy for surgically resectable pancreatic adenocarcinoma; Diagnosis and management of borderline resectable pancreatic adenocarcinoma; Treatment approaches to locally advanced pancreatic adenocarcinoma; Therapeutic approaches for metastatic pancreatic adenocarcinoma; Supportive and end-of-life care for patients with pancreatic adenocarcinoma; and Novel therapeutics for pancreatic adenocarcinoma.

Sujets

• Hermatology
• Medical
• Médecine

Informations

• Publié par: Elsevier
• Date de parution: 12 novembre 2015
• Nombre de lectures: 0
• EAN13: 9780323393379
• Langue: English
• Poids de l'ouvrage: 1 Mo

Extrait

Clinics Review Articles HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA
Pancreatic Cancer

Brian M. Wolpin, MD, MPH
Center for Gastrointestinal Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
ISSN  0889-8588 Volume 29 • Number 4 • August 2015
Elsevier
Table of Contents
Cover image
Title page
Copyright
Contributors
Consulting Editors
Editor
Authors
Forthcoming Issues
Forthcoming Issues
Recent Issues
Preface: Pancreatic Cancer
Genetics and Biology of Pancreatic Ductal Adenocarcinoma
Key points
Genetics
KRAS
Microenvironment
Immune response
Metabolic requirements
Summary
Mouse Models of Pancreatic Ductal Adenocarcinoma
Key points
Introduction
Mouse xenograft models
Genetically engineered mouse models
Future directions
Epidemiology and Inherited Predisposition for Sporadic Pancreatic Adenocarcinoma
Key points
Epidemiology for pancreatic adenocarcinoma
Inherited predisposition for sporadic pancreatic adenocarcinoma
Summary
Familial Pancreatic Adenocarcinoma
Key points
Introduction
Evidence for genetic basis of pancreatic cancer
Genetic studies of familial pancreatic cancer
Clinical translation of familial pancreatic cancer research
Summary
Diagnosis and Management of Pancreatic Cystic Neoplasms
Key points
Introduction
Disease entities
General approach to diagnosis and management
Outcomes
Summary and discussion
Imaging and Endoscopic Approaches to Pancreatic Cancer
Key points
Introduction
Noninvasive imaging in pancreatic cancer
Endoscopy in pancreatic cancer
Summary
Surgery for Pancreatic Cancer
Key points
Introduction
Indications/Contraindications
Technique/Procedure
Complications and management
Outcomes
Controversies/Future considerations
Summary
Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma
Key points
Introduction
Definition of resectable pancreatic adenocarcinoma
Adjuvant therapy
Neoadjuvant therapy
Biomarkers predictive of outcome
What is on the horizon
Summary
Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma
Key points
Introduction
Definitions
Diagnosis and staging
Management
Surgical issues
Summary
Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma
Key points
Introduction
Definition of locally advanced pancreatic cancer: accurate diagnosis and staging
Treatment of locally advanced pancreatic cancer
Systemic therapy in locally advanced pancreatic cancer
Advances in pancreatic radiation techniques
Stereotactic body radiotherapy
Summary/discussion
Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma
Key points
Introduction
Patient evaluation and prognostic markers
Gemcitabine
Folinic acid, 5-fluorouracil, irinotecan, oxaliplatin
Gemcitabine plus nab-paclitaxel
Folinic acid, 5-fluorouracil, irinotecan, oxaliplatin versus gemcitabine plus nab-paclitaxel
Second-line therapy
New approaches
Summary
Novel Therapeutics for Pancreatic Adenocarcinoma
Key points
Immunotherapy
GVAX, CRS207 vaccines
Hyperacute vaccination
Checkpoint blockade
Immune microenvironment
T-cell manipulation
BRCA-related therapies and poly-ADP ribose polymerase inhibitors
Molecularly targeted therapies
Targeting KRAS
JAK-STAT pathway and inflammation
Autophagy
Notch and stem cell targeting
Stromal targeting therapies
PEGPH20
TH302
Necuparanib
Novel cytotoxic formulations
Summary
Index
Copyright
ELSEVIER
1600 John F. Kennedy Boulevard • Suite 1800 • Philadelphia, Pennsylvania, 19103-2899
http://www.theclinics.com
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA Volume 29, Number 4
August 2015 ISSN 0889-8588, ISBN 13: 978-0-323-39336-2
Editor: Jennifer Flynn-Briggs
Developmental Editor: Donald Mumford
© 2015 Elsevier Inc. All rights reserved.
This periodical and the individual contributions contained in it are protected under copyright by Elsevier, and the following terms and conditions apply to their use:
Photocopying
Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: ([phone] (UK)/([phone] (USA).
Derivative Works
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions ).
Electronic Storage or Usage
Permission of the Publisher is required to store or use electronically any material contained in this periodical, including any article or part of an article (please consult www.elsevier.com/permissions ). Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.
Notice
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.
Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Hematology/Oncology Clinics (ISSN 0889-8588) is published bimonthly by Elsevier Inc., 360 Park Avenue South, NewYork, NY10010-1710. Months of issue are February, April, June, August, October, and December. Business and Editorial Offices: 1600 John F. Kennedy Blvd., Ste. 1800, Philadelphia, PA 19103–2899. Customer Service Office: 3251 Riverport Lane, Maryland Heights, MO63043. Periodicals postage paid at New York, NY and at additional mailing offices. Subscription prices are $385.00 per year (domestic individuals), $633.00 per year (domestic institutions), $190.00 per year (domestic students/residents), $440.00 per year (Canadian individuals), $783.00 per year (Canadian institutions) $520.00 per year (international individuals), $783.00 per year (international institutions), and $255.00 per year (international and Canadian students/residents). International air speed delivery is included in all Clinics subscription prices. All prices are subject to change without notice. POSTMASTER: Send address changes to Hematology/Oncology Clinics of North America , Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043. Customer Service (orders, claims, online, change of address): Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043. Tel: [phone] (U.S. and Canada); 314-447-8871 (outside U.S. and Canada). Fax: [phone]. E-mail: [e-mail] (for print support) ; [e-mail] (for online support) .
Reprints. For copies of 100 or more, of articles in this publication, please contact the Commercial Reprints Department, Elsevier Inc., 360 Park Avenue South, New York, New York 10010-1710; Tel.: [phone], Fax: [phone], E-mail: [e-mail] .
Hematology/Oncology Clinics of North America is covered in MEDLINE/PubMed (Index Medicus), EMBASE/Excerpta Medica, and BIOSIS.
Printed in the United States of America.
Contributors

Consulting Editors
GEORGE P. CANELLOS, MD
William Rosenberg Professor of Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
H. FRANKLIN BUNN, MD
Professor of Medicine, Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Editor
BRIAN M. WOLPIN, MD, MPH
Co-Director, Pancreas and Biliary Tumor Center, Department of Medical Oncology, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Authors
LAUFEY T. AMUNDADOTTIR, PhD
Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
THOMAS E. CLANCY, MD